GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future ...

On average, without antiretroviral medications (ART), chronic HIV will progress to AIDS in five to 10 years, though it may be faster in some people. That said, there are now 39 million people living ...

HIV-1, like other viruses, lacks the machinery to produce ... offering a promising new avenue for antiviral drug development”, reports Caliskan. Redmond Smyth, a former Helmholtz Young Investigator ...

HIV-1, like other viruses ... offering a promising new avenue for antiviral drug development”, reports Caliskan. The researchers also observed that ribosomes collide at specific regions of ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...

Citation: Flu antiviral baloxavir shows promise over other treatments for high-risk patients, shortening symptom duration (2025, January 16) retrieved 29 January 2025 from https://medicalxpress ...

A SYSTEMATIC review and meta-analysis evaluating antiviral medications for nonsevere influenza provides new insights into the optimal treatments for symptom relief and hospitalization risks, ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...